Mantle Cell Lymphoma

FDA approval · 2020-08-07

FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)

FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.

CLINICAL_TRIALS trial_result · 2020-07-01

Clinical Trial Update: Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma [Phase 2]

Phase 2 trial update for oral enzastaurin in relapsed mantle cell lymphoma has completed with results posted.

CLINICAL_TRIALS trial_result · 2020-06-23

Clinical Trial Update: Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 2]

Phase 2 trial evaluating ofatumumab-based regimens for newly diagnosed mantle cell lymphoma has completed with results posted.

CLINICAL_TRIALS trial_result · 2020-06-23

Clinical Trial Update: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL [Phase 1]

This report summarizes results from a Phase I/Ib safety and preliminary efficacy study of the PI3K-delta inhibitor TGR-1202 in combination w…

CLINICAL_TRIALS trial_result · 2020-06-02

Clinical Trial Update: Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies [Phase 2]

Phase 2 trial of Entospletinib plus Idelalisib in adults with relapsed or refractory hematologic malignancies was terminated; results posted…

CLINICAL_TRIALS trial_result · 2020-05-13

Clinical Trial Update: Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) [Phase 2]

Phase 2 trial evaluating the efficacy and safety of zanubrutinib (BGB-3111) in relapsed or refractory mantle cell lymphoma has completed wit…

CLINICAL_TRIALS trial_result · 2020-05-12

Clinical Trial Update: Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas [Phase 1, Phase 2]

Phase 1/2 trial evaluating pembrolizumab in patients with diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma who f…

CLINICAL_TRIALS trial_result · 2020-05-07

Clinical Trial Update: Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia [Phase 2]

Phase 2 safety and tolerability study of PCI-32765 in various B-cell malignancies completed; results posted.

CLINICAL_TRIALS trial_result · 2020-04-24

Clinical Trial Update: A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]

Phase 2 trial evaluating the combination of ibrutinib, lenalidomide, and rituximab in relapsed/refractory mantle cell lymphoma has completed…

FDA approval · 2020-04-21

FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)

FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.

CLINICAL_TRIALS trial_result · 2020-04-09

Clinical Trial Update: Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma [Phase 2]

Phase 2 trial evaluating flavopiridol in patients with previously untreated or relapsed mantle cell lymphoma has completed.

CLINICAL_TRIALS trial_result · 2020-03-23

Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]

Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.

CLINICAL_TRIALS trial_result · 2020-02-24

Clinical Trial Update: Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]

Phase 1/2 study evaluating lenalidomide plus rituximab in relapsed mantle cell lymphoma and diffuse large B-cell lymphoma; trial completed w…

CLINICAL_TRIALS trial_result · 2020-01-27

Clinical Trial Update: Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT [Phase 2]

Phase II trial update examining maintenance subcutaneous rituximab after induction in relapsed mantle cell lymphoma and non-eligible for hem…

CLINICAL_TRIALS trial_result · 2020-01-13

Clinical Trial Update: Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL [Phase 2]

Phase 2 clinical trial update for a CpG-activated whole cell vaccine followed by autologous immunotransplant in mantle cell lymphoma; trial …

CLINICAL_TRIALS trial_result · 2020-01-03

Clinical Trial Update: Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL [Phase 1, Phase 2]

Phase 1/2 trial evaluating VSLI plus rituximab in relapsed/refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mant…

CLINICAL_TRIALS trial_result · 2019-12-09

Clinical Trial Update: Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant [Phase 2]

Phase 2 trial investigating sirolimus, cyclosporine, and mycophenolate mofetil to prevent graft-versus-host disease in patients with blood c…

CLINICAL_TRIALS trial_result · 2019-11-22

Clinical Trial Update: Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies [Phase 2]

Phase 2 clinical trial assessing donor atorvastatin to prevent severe acute GVHD after nonmyeloablative peripheral blood stem cell transplan…

CLINICAL_TRIALS trial_result · 2019-11-08

Clinical Trial Update: Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma [Phase 1, Phase 2]

A combined Phase 1/2 trial evaluating lenalidomide after chemotherapy and stem cell transplant in various forms of recurrent or resistant no…

CLINICAL_TRIALS trial_result · 2019-10-22

Clinical Trial Update: Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma [Phase 2]

Phase 2 clinical trial of bortezomib, cladribine, and rituximab in advanced mantle cell lymphoma or indolent lymphoma has completed with res…

CLINICAL_TRIALS trial_result · 2019-10-11

Clinical Trial Update: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [Phase 2]

Phase 2 clinical trial update on donor umbilical cord blood transplant for hematologic cancers; status completed with results posted.

FDA label_change · 2019-10-08

FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) by Teva Pharmaceuticals to update its labeling.

CLINICAL_TRIALS trial_result · 2019-09-16

Clinical Trial Update: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) [Phase 2]

Phase 2 trial comparing lenalidomide to investigator's choice in relapsed or refractory mantle cell lymphoma has completed; results posted i…

CLINICAL_TRIALS trial_result · 2019-05-01

Clinical Trial Update: A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]

A Phase II study evaluating carfilzomib for relapsed or refractory mantle cell lymphoma has been terminated, with results posted in 2019.

CLINICAL_TRIALS trial_result · 2019-04-17

Clinical Trial Update: Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 [Phase 1, Phase 2]

Phase 1/2 clinical trial evaluating tandem CAR T cells targeting CD19 and CD22 for relapsed or chemotherapy-refractory B-cell malignancies.

Top drugs studied for this disease